Brief: Cipher Pharmaceuticals Announces Partner Moberg Pharma's Submission To FDA For North American Phase 3 Study
22/03/2022 21:27
March 22 (Reuters) - Cipher Pharmaceuticals Inc CPH.TO :
* CIPHER PHARMACEUTICALS ANNOUNCES PARTNER, MOBERG PHARMA'S
REGULATORY SUBMISSION TO FDA FOR NORTH AMERICAN PHASE 3 STUDY
Source text for Eikon: ID:nCNWlYB6Pa
Further company coverage: CPH.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Cipher Pharmaceuticals
See all newsBrief: Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award
Canada's Cipher Pharma Q2 revenue falls on lower Natroba sales amid reduced Medicaid coverage
Canada Research Roundup: Altius Minerals, Cipher Pharmaceuticals, Suncor Energy
Canada's Cipher Pharmaceuticals Q1 net income jumps 135% on lower costs
Brief: Cipher Pharmaceuticals Q1 Net Income USD 6.163 Million